JPS603048B2 - Digestive system disease treatment - Google Patents
Digestive system disease treatmentInfo
- Publication number
- JPS603048B2 JPS603048B2 JP102776A JP102776A JPS603048B2 JP S603048 B2 JPS603048 B2 JP S603048B2 JP 102776 A JP102776 A JP 102776A JP 102776 A JP102776 A JP 102776A JP S603048 B2 JPS603048 B2 JP S603048B2
- Authority
- JP
- Japan
- Prior art keywords
- digestive system
- gastric
- stomach
- disease treatment
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 本発明は、一般式 (式中、Rはピリジルまたはチェニルを示す。[Detailed description of the invention] The present invention is based on the general formula (In the formula, R represents pyridyl or chenyl.
)で表わされるモルホリン誘導体またはその酸付加塩を
主成分とする消化器系疾患治療剤に関する。) or an acid addition salt thereof as a main component.
従来から、胃・十二指腸簿湯、胃・陽連れん、胃酸過多
症などの消化器系疾患の治療に広く用いられている抗ア
セチルコリン作用を有する、いわゆる抗コリン剤には腫
孔散大、口潟などの好ましくない作用が見られ、、副作
用の面から見てかなり問題があに、抗コリン剤に代るべ
き消化器系用薬剤の開発が強く望まれていた。本発明者
らは、一般式〔1〕の化合物またはその酸付加塩は抗ア
セチルコリン作用が極めて低いにも拘らず、抗漬嫁作用
、胃液分泌仰制作用などを有し消化器系用薬剤として有
用であることを見出し本発明を完成するに至った。Conventionally, so-called anticholinergic drugs with antiacetylcholine effects, which have been widely used in the treatment of gastrointestinal diseases such as gastric and duodenobobito, gastric and yang irritability, and gastric hyperacidity, have the effect of increasing tumor size and mouth. Unfavorable effects such as lag were observed, and there were considerable problems in terms of side effects, and there was a strong desire to develop a drug for the digestive system that could replace anticholinergic drugs. The present inventors have discovered that although the compound of general formula [1] or its acid addition salt has extremely low anti-acetylcholine activity, it has anti-cholinergic activity, suppresses gastric secretion, etc., and is used as a drug for the digestive system. The present inventors have found that the invention is useful and have completed the present invention.
一般式〔1〕の化合物またはその酸付加塩は、樽関略4
9−82676号、持関昭50一8938び号の各明細
旨にその製造法が記載されているが、いまだ、消化器系
疾患への適用については知られていない。The compound of general formula [1] or its acid addition salt is
Although the manufacturing method is described in the specifications of No. 9-82676 and Mochiseki No. 50-18938, its application to gastrointestinal diseases is not yet known.
本発明に用いられる代表的化合物は次の通りである。2
一〔2一(2−テニル)フエノキシメチル〕モルホリン
・マレィン酸塩 融点155〜156℃夕−2一〔2一
(2−テニル)フエノキシメチル〕モルホリン・マレィ
ン酸塩 融点128〜129℃〔Q〕20/D一5.0
ず(cl.01、メタノール)2一〔2一(2−ピリジ
ルメチル)フヱ/キシメ秋〕机机ン‐1裏フマ−暇塩脱
,32〜1父。Representative compounds used in the present invention are as follows. 2
1[2-(2-tenyl)phenoxymethyl]morpholine maleate Melting point 155-156℃ E-21[2-(2-tenyl)phenoxymethyl]morpholine maleate Melting point 128-129℃[Q]20/ D-5.0
Zu (cl. 01, methanol) 21 [21 (2-pyridylmethyl) fluoride/Kishime Aki] Machine-1 Ura Fuma-Yashio De, 32-1 father.
0
2−〔3一(2−ピリジルメチル)フエノキシメチル〕
モルホリン・マレィン酸塩 融点130〜13鱗○次に
、一般式〔1〕の化合物またはその酸付加塩が抗涜傷作
用、胃液分泌仰制作用などを有することを実験方法とと
もに示す。0 2-[3-(2-pyridylmethyl)phenoxymethyl]
Morpholine maleate Melting point: 130-13 Next, we will show, along with experimental methods, that the compound of general formula [1] or its acid addition salt has anti-fouling effects, suppressing gastric juice secretion, and the like.
01 ストレス簿湯に対する作用
高木らの方法〔ジャパニーズ・ジャーナル・オブ・ファ
ーマコロジィ(Jap.J.P的rmac.)第18巻
9〜18ページ(196洋王)〕を改変して行った。01 Effect on stress stress The method of Takagi et al. [Japanese Journal of Pharmacology (Jap.
体重160タ前後の雌性Wistarラットを20時間
絶食させた後、ストレスケージに入れて拘束し、22℃
の水に浸した。6時間後にエーテルで、屠殺し、胃の中
へ8泌の1%ホルマリン溶液を注入し、固定した。After fasting female Wistar rats weighing around 160 ta for 20 hours, they were restrained in stress cages and kept at 22°C.
soaked in water. After 6 hours, the animals were sacrificed with ether and fixed by injecting 8 volumes of 1% formalin solution into their stomachs.
胃を切開し、胃損傷部分の長径の総和を対数変換して薄
場指数とした。試験化合物はストレス負荷30分前に経
口投与した。The stomach was incised, and the sum of the major axes of the injured part of the stomach was logarithmically transformed to obtain the thin field index. The test compound was orally administered 30 minutes before stress loading.
なお、試験化合物による仰制率を下式により算出し、つ
いで、この仰制率を投与量(のp/k9)に対して半対
数グラフにプロットしてED5。Incidentally, the supine rate due to the test compound was calculated by the following formula, and then this supine rate was plotted on a semi-log graph against the dose (p/k9) to calculate the ED5.
値を求めた。■ Shay濃湯に対する作用Shayら
の方法〔ガストロェンテロロジ‐(Gasooente
rolo戦)第5巻43〜61ページ(1処5年)〕を
改変して行った。I found the value. ■ Effect on Shay hot water [Gastroenterology] Shay et al.'s method
Rolo Battle) Volume 5, pages 43-61 (1st place 5th year)] was modified.
体重160多前後の雌性Wistarラツトを44時間
個別ケージに入れて絶食(水は自由に与えた)後、エー
テル麻酔下に幽門を鯖※し、lq時間絶食絶水下に放置
した。Female Wistar rats weighing around 160 kg were placed in individual cages for 44 hours and fasted (water was provided ad libitum), then the pylorus was sacrifuged under ether anesthesia and left without food or water for 1q hours.
エーテル屠殺後、贋門から胃内容物を目盛り付き遠心管
に採取し、300仇pm,1企分間遠心して、上澄液の
量から100タ体重当りの胃液量を求めた。また胃内容
物採取後、胃の中へ8の‘の1%ホルマリン溶液を注入
し、固定した。ついで、胃を切開し、損傷部分の面積の
総和を対数変換して濃蕩指数とした。試験化合物は、幽
門結繋直後に皮下投与した。After ether sacrificing, the stomach contents were collected from the mice into graduated centrifuge tubes, centrifuged at 300 pm for 1 minute, and the amount of gastric juice per 100 ta body weight was determined from the amount of supernatant. After collecting the gastric contents, a 1% formalin solution was injected into the stomach to fix it. Then, the stomach was incised, and the total area of the injured area was logarithmically transformed to obtain the concentration index. Test compounds were administered subcutaneously immediately after pylorus ligation.
試験化合物による仰制率を下式により算出し、つ1,、
で、この仰制率を投与量(秘/【9)に対して半対数グ
ラフにプロットしてEは。値を求めた。【3’ アスピ
リン簿場に対する作用体重150タ前後の磁性Wist
arラットを24時間絶食後、アスピリン100のp/
k9を経口投与し、5時間絶食麹水下に放置した。The supine rate due to the test compound was calculated using the following formula,
Then, plot this supine rate against the dose (secret/[9) on a semi-logarithmic graph and get E. I found the value. [3' Magnetic Wist with a weight of around 150 ta that acts on aspirin storage
After fasting ar rats for 24 hours, aspirin 100 p/
K9 was orally administered and left in fasted koji water for 5 hours.
エーテル屠殺後、胃の中ヘボンタミン・スカイブルー・
曲を0.2%の割合で含む1%ホルマリン溶液を8の【
注入し固定した。胃の切開後、胃粘液を拭き取り染色さ
れた胃損傷部分の長経の総和を対数変換して濃蕩指数と
した。試験化合物はアスピリン投与30分前に皮下投与
した。After ether slaughter, Hevontamin sky blue in the stomach.
Add 1% formalin solution containing 0.2% of music to 8 [
Injected and fixed. After the stomach was incised, the gastric mucus was wiped off and the sum of the longitudinal lengths of the stained injured part of the stomach was logarithmically transformed to obtain the concentration index. Test compounds were administered subcutaneously 30 minutes before aspirin administration.
試験化合物による仰制率を下式から求め、ついで、この
仰制率を投与量(雌/kg)に対して半対数グラフにプ
ロットしてED5。値を求めた。‘4} ヒスタミン債
湯に対する作用Bagetonらの方法〔ジャーナル・
オブ・バソロジー・アンド・バクテリオロジー(Jo肌
alofPathologyand舷cteriolo
gy)第9鏡萱679〜682ページ(1965)〕を
改変して行った。The rate of supineness due to the test compound is determined from the following formula, and then this rate of supineness is plotted on a semi-logarithmic graph against the dose (female/kg) to calculate ED5. I found the value. '4} Effect on histamine bonds Method of Bageton et al. [Journal.
Of Pathology and Bacteriolo
gy) No. 9 Kyogaya, pages 679-682 (1965)].
体重700タ前後の雄性白色モルモットを2餌時間個別
ケージに入れて絶食後、ヒスタミン燐酸塩5の3/k9
を腹腔内へ投与した。Male white guinea pigs weighing around 700 ta were placed in individual cages for 2 feeding hours and after fasting, 3/k9 of histamine phosphate 5 was added.
was administered intraperitoneally.
2時間後に撲殺し、胃の中へ30の‘の1%ホルマリン
溶液を注入し、固定した。Two hours later, the animals were killed by buffeting, and 30 minutes of 1% formalin solution was injected into the stomach to fix it.
5分後に胃を切開し、胃損傷部分の面積の総和を対数変
換して薄賜指数とした。After 5 minutes, the stomach was incised, and the total area of the injured part of the stomach was logarithmically transformed and used as the thinning index.
試験化合物はヒスタミン投与3び分前に皮下投与した。The test compound was administered subcutaneously 3 minutes before histamine administration.
試験化合物による仰制率を下式より求め、ついで、この
仰制率を投与量(の9/k9)に対して半対数グラフに
プロットしてED5。値を求めた。‘51 ストレス負
荷時の胃連動冗進に対する作用渡辺の方法〔ケミカル・
アンド・ファーマシユーテイカル・ブレテイン(Che
mical andPharm舷‐ce山icaIBu
lletin)第14巻101〜10刀頁(196母王
)〕を用いEは。値を求めた。‘61Shay胃液分泌
に対する作用Shayらの方法〔ガストロェンテロロジ
‐(Gas口肥nterolo野)第5巻43〜61ペ
ージ(1凶5)〕も改変して行った。The supine rate due to the test compound is determined by the following formula, and then this supine rate is plotted on a semi-log graph against the dose (9/k9) to calculate ED5. I found the value. '51 Effect of Watanabe's method on gastric hyperactivity under stress [Chemical
and Pharmaceutical Bulletin (Che
mical and Pharm port-ce mountain icaIBu
lletin) Volume 14, pages 101-10 (196 Mother King)] is used for E. I found the value. '61 Shay Effect on gastric juice secretion The method of Shay et al. [Gastroenterology Vol. 5, pages 43-61 (1-5)] was also modified.
体重200タ前後の雄性Wistarラットを48時間
個別ケージに入れて絶食(水は自由に与えた)後エーテ
ル麻酔下に幽門を緒繁した。Male Wistar rats weighing around 200 ta were kept in individual cages for 48 hours, fasted (water was given ad libitum), and then the pylorus was removed under ether anesthesia.
閉腹後、5の‘の生理食塩水を腹腔内投与し、4時間給
食絶水下に放置した。エーテル屠殺後、食道を鯖繁して
費を取り出した。胃内容物を目盛り付き遠心管に採取し
、300比pm,10分間遠心分離後、上澄液の量から
体重100夕当りの胃液分泌量を求めた。試験化合物は
幽門結繋直後に皮下投与した。試験化合物による仰制率
を下式により求め、ついで、この仰制率を投与量(滋/
kg)に対して半対数グラフにプロットしてEは。値を
求めた。‘71 抗アセチルコリン作用J.MVanR
ossumらの方法〔アルシーヴ・ヱンテルナシオナル
・ド・フアルマコデイナミー・エ・テラピ−(〜chi
ves lnにrMtionales dePharm
acの如amjeetdeTherapie、第14窃
蓋240〜246ページおよび299〜斑0ページ(1
9成年)〕により行い、pらを求めた。After abdominal closure, 5 minutes of physiological saline was administered intraperitoneally, and the animals were left without food or water for 4 hours. After the ether slaughter, the esophagus was pierced and the body was extracted. The gastric contents were collected into a graduated centrifuge tube and centrifuged at 300 pm for 10 minutes, and the amount of gastric juice secreted per 100 kg of body weight was determined from the amount of supernatant. The test compound was administered subcutaneously immediately after pylorus ligation. The supine rate due to the test compound is determined by the following formula, and then this supine rate is calculated as the dose (Shiguru/
kg) on a semi-logarithmic graph. I found the value. '71 Antiacetylcholine effect J. MVanR
The method of Ossum et al.
ves ln rMtionales de Pharm
ac's like amjeet de Therapy, 14th page 240-246 and 299-0 page (1
9 adults)], and p et al.
‘81 急性菱性値Litchfield−wilco
xon法によりフウスでLD別値(経口)を求めた。'81 Acute Rhombic Value Litchfield-Wilco
LD-specific values (oral) were determined by Fuuss using the xon method.
以上の実験による結果を第1表にまとめた。The results of the above experiments are summarized in Table 1.
第1表以上の実験結果から明らかなように、一般式〔1
)の化合物またはその酸付加塩は、胃・十二指腸簿湯、
急性または慢性胃炎、胃酸過多症、胃腸管辱れんなどの
治療および予防、さらにはストレスで起こる胃・十二指
腸溝糠の予防のための医薬として有用である。As is clear from the experimental results in Table 1 and above, the general formula [1
) compounds or their acid addition salts are
It is useful as a medicine for the treatment and prevention of acute or chronic gastritis, gastric hyperacidity, gastrointestinal tract upset, etc., and also for the prevention of gastric and duodenal sulcus due to stress.
一般式〔1〕の化合物またはその酸付加塩は、それ自体
あるいは適宜の薬理的に許容される燈体、賦形剤、希釈
剤と混合し、粉末、親粒、錠剤、カプセル剤、注射剤な
どの形態で経口的また非経口的に投与することができる
。The compound of general formula [1] or its acid addition salt can be prepared by itself or mixed with appropriate pharmacologically acceptable substances, excipients, and diluents to form powders, parent granules, tablets, capsules, and injections. It can be administered orally or parenterally.
投与量は、たとえば成人の場合、以の組成を有する錠剤
を1日3錠からla碇を経口的に投薬されるが、年令、
体重、症状などにより投与量が増減されることはいうま
でもない。組成例The dosage for adults is, for example, 3 tablets per day with the following composition, but depending on the age,
Needless to say, the dosage may be adjusted depending on body weight, symptoms, etc. Composition example
Claims (1)
主成分とする消化器系疾患治療剤。[Claims] 1. A digestive system whose main component is a morpholine derivative represented by the general formula ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (in the formula, R represents pyridyl or thienyl) or its acid addition acid. Disease treatment agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP102776A JPS603048B2 (en) | 1976-01-05 | 1976-01-05 | Digestive system disease treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP102776A JPS603048B2 (en) | 1976-01-05 | 1976-01-05 | Digestive system disease treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5287242A JPS5287242A (en) | 1977-07-20 |
| JPS603048B2 true JPS603048B2 (en) | 1985-01-25 |
Family
ID=11490068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP102776A Expired JPS603048B2 (en) | 1976-01-05 | 1976-01-05 | Digestive system disease treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS603048B2 (en) |
-
1976
- 1976-01-05 JP JP102776A patent/JPS603048B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5287242A (en) | 1977-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201406711A (en) | Cystathionine- γ -lyase (CSE) inhibitors | |
| JPS59196877A (en) | Thiazolidine derivative | |
| CN1008062B (en) | Method for preparing improved anti-inflammatory drug Yantongxikang salts | |
| CN113599382B (en) | Application of quinoline derivatives in preparation of medicines for treating diabetes and complications thereof | |
| US20260001872A1 (en) | Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof | |
| KR940011244B1 (en) | Kidney disease treatment | |
| CN115304590B (en) | 2H-benzotriazole derivatives and preparation methods thereof and pharmaceutical compositions containing them | |
| JPH0428245B2 (en) | ||
| JPS62181246A (en) | Novel oxidated alkyl derivatives of glutamic acids and aspartic acids having antagonistic activity against bioactive polypeptides and manufacture | |
| CN113599385B (en) | Application of alfuzosin in preparing medicine for treating diabetes and complications thereof | |
| JPS62207212A (en) | Antiallergic agent | |
| AU2024203992B2 (en) | Prophylactic or therapeutic agent for porphyria | |
| JPH0475205B2 (en) | ||
| JPS603048B2 (en) | Digestive system disease treatment | |
| CN1259914C (en) | Use of scopoletin in preparing medicine for preventing and curing hyperuricemia | |
| JP3253878B2 (en) | Formulations for iron chelation, methods of preparing the same and methods of treating Mediterranean anemia | |
| JP2024529777A (en) | Pharmaceutical compositions and applications of ARNi and calcium ion antagonists | |
| JPH05504130A (en) | Tumor necrosis factor antagonist | |
| JPS59508B2 (en) | 2 3- Chikan -4- Fusokandiyouaminosulfonylbenzenesulfonamide | |
| JPS6056123B2 (en) | Agent for treating edema, hypotension, heart failure, and mucosal hyperemia | |
| JPH0742227B2 (en) | Kidney disease treatment | |
| US3708581A (en) | Anti-inflammatories | |
| JPS6133804B2 (en) | ||
| CN107456454A (en) | A kind of pharmaceutical composition prevented or treat inflammatory disease | |
| JPS5812256B2 (en) | Medications for treating stomach ulcers, etc. |